<DOC>
	<DOCNO>NCT00005896</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine safety transfer Fanconi anemia complementation group C ( FACC ) gene hematopoietic progenitor retroviral mediate gene transfer patient Fanconi 's anemia , complementation group C. II . Determine extent engraftment follow treatment regimen without prior ablation recipient marrow patient . III . Determine ability treatment regimen correct cell phenotype improve hematopoietic function patient .</brief_summary>
	<brief_title>Phase I Pilot Study CD34 Enriched , Fanconi 's Anemia Complementation Group C Gene Transduced Autologous Peripheral Blood Stem Cell Transplantation Patients With Fanconi 's Anemia</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive filgrastim ( G-CSF ) subcutaneously daily day 0-6 followed apheresis collect peripheral blood stem cell ( PBSC ) day 5-7 . PBSCs process vitro enrichment CD34 cell transduce Fanconi 's anemia complementation C ( FACC ) retroviral vector day 5-10 . Patients receive transduce PBSCs IV 2 hour day 8-10 . PBSC infusion may repeat every 2 month 4 course total . Patients follow monthly 3 month , every 3 month 9 month , every 6 month next year , yearly thereafter .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Fanconi 's anemia , complementation group C ( FACC ) Confirmed diepoxybutane mitomycin test AND DNA analysis indicate FACC mutation Patients least 25 kg weight No acute leukemia OR Bone marrow aspirate great 10 % blast No patient elect bone marrow transplantation Prior/Concurrent Therapy At least 14 day since prior therapy acute viral , bacterial , fungal infection Patient Characteristics Performance status : Karnofsky 40100 % Hepatic : SGOT , SGPT , alkaline phosphatase great 5 time upper limit normal ( ULN ) PT/PTT great 1.5 time ULN Serum amylase great 1.5 time ULN Bilirubin great 2.5 mg/dL Triglyceride le 400 mg/dL Renal : Creatinine clearance great 50 mL/min Cardiovascular : Normal cardiac function No ischemic heart disease may consider anesthetic operative risk Pulmonary : No lung disease may consider anesthetic operative risk Resting transcutaneous oxygen saturation great 90 % room air Other : HIV negative Hepatitis B surface antigen negative No underlie condition may preclude study therapy ( e.g. , allergy study reagent ) No acute viral , bacterial , fungal infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2001</verification_date>
	<keyword>Fanconi 's anemia</keyword>
	<keyword>aplastic anemia</keyword>
	<keyword>hematologic disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>